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Abstract Whole transcriptome studies have used 3′-biased
expression microarrays to study genes regulated in the blood
of stroke patients. However, alternatively spliced messenger
RNA isoforms have not been investigated for ischemic stroke
or intracerebral hemorrhage (ICH) in animals or humans.
Alternative splicing is the mechanism whereby different com-
binations of exons of a single gene produce distinct mRNA
and protein isoforms. Here, we used RNA sequencing (RNA-
seq) to determine if alternative splicing differs for ICH and
cardioembolic, large vessel and lacunar causes of ischemic
stroke compared to controls. RNA libraries from 20 whole
blood samples were sequenced to 200 M 2×100 bp reads
using Illumina sequencing-by-synthesis technology.
Differential alternative splicing was assessed using one-way
analysis of variance (ANOVA), and differential exon usage
was calculated. Four hundred twelve genes displayed differ-
ential alternative splicing among the groups (false discovery
rate, FDR; p<0.05). They were involved in cellular immune
response, cell death, and cell survival pathways. Distinct ex-
pression signatures based on usage of 308 exons (292 genes)
differentiated the groups (p<0.0005; fold change >|1.2|). This
pilot study demonstrates that alternatively spliced genes from
whole blood differ in ICH compared to ischemic stroke and
differ between different ischemic stroke etiologies. These re-
sults require validation in a separate cohort.
Keywords Ischemic stroke . Intracerebral hemorrhage .
Alternative splicing . Biomarkers . RNA-seq . Exon
Introduction
Stroke is diagnosed based on patient history, neurological ex-
am, and brain imaging. Differential diagnosis can be difficult
particularly for distinguishing ischemic stroke (IS) from intra-
cerebral hemorrhage (ICH) when imaging is unavailable in
the acute setting. Thus, an accurate, inexpensive, and rapid
blood test would be useful.
Blood transcriptomes show promise as diagnostic bio-
markers and have provided insight into understanding the na-
ture of the immune response following human stroke [1–6].
However, these studies have investigated only a portion of the
protein coding transcriptome, since they have used 3′-biased
microarrays to measure blood mRNA expression [1–6].
Though these studies demonstrated proof-of-principle, most
of the stroke transcriptome which is comprised of all alterna-
tively spliced isoforms remains unstudied in stroke. The im-
portance of alternative splicing is supported by evidence im-
plicating it in the pathogenesis of many diseases [7, 8] .
Alternative splicing is the process whereby exons from a
single gene are included or excluded in the final mRNA tran-
script (Supplementary Figure 1). A single gene can produce
several alternatively spliced isoforms which have specific
functions in different cells, tissues, developmental stages,
and disease states. Thus, the ~20,000 known genes code for
>250,000 different mRNAs and proteins. Differential alterna-
tive splicing (DAS) is alternative splicing that differs between
groups. We hypothesized that DAS would vary for different
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causes of IS (cardioembolic, large vessel, and lacunar) and for
ICH when compared to each other and to controls.
RNA-seq is a new technology that allows for estimation of
expression of each splice variant (Supplementary Figure 1), a
significant advance over previous technologies. Because there
have been no studies of alternative splicing related to stroke
etiology, or for IS versus ICH either in humans or in animal
models, we performed this pilot RNA-seq study to examine
DAS in whole blood following IS and ICH in humans.
Methods
Stroke patients and control subjects were randomly selected
from those recruited at the University of California Davis
Medical Center between 2008 and 2012. Stroke patients were
chosen to represent the major IS etiologies (cardioembolic,
large vessel atherosclerotic, lacunar) or had ICH. IS diagnosis
and causes were assessed as described previously [5, 9]. ICH
patients had deep ICH (basal ganglia, deep white matter, or
thalamus) confirmed by CT and/or MRI brain scans and were
associated with hypertension without evidence of vascular
malformation, tumor, or aneurysm. Control subjects were se-
lected to match stroke subjects for age, race, sex, and vascular
risk factors and had no history of previous stroke or cardio-
vascular events. Blood from all subjects was drawn into
PAXgene tubes between 5.8 and 101.2 h following IS or
ICH. RNA from whole blood was isolated as previously de-
scribed [3]. The UCD Institutional Review Board approved
this study and all subjects provided informed consent.
Whole blood RNA was used to prepare mRNA libraries
using the TruSeq RNA Sample Prep v2 kit and protocol
(Illumina). Two hundred million PE 100-bp RNA-seq reads
were obtained from eachmRNA library using Illumina Solexa
sequencing by synthesis on the Illumina HiSeq 2000. TopHat
v2.0.7 (Bowtie v2.0.6) was used with default parameters to
map reads to a reference genome (Hg19) and generate bam
files for analysis [10]. RNA transcript quantification was
performed using Hg19 AceView transcripts in the Partek
Genomics Suite 6.6 RNA-seq workflow.
The raw reads for genes displaying DAS are shown in
Supplementary Table 2 and the raw reads for genes displaying
differential exon usage are shown in Supplementary Table 6.
They were generated from aligned bam files using
featureCounts against AceView (NCBI 37) [11] with options
allowing for any and multiple overlaps [12]. However, they
were not used directly for the statistical analysis. Instead, raw
aligned reads were normalized, and differential alternatively
spliced transcript expression and exon expression quantification
were performed using the expectation/maximization (E/M) al-
gorithm (briefly described below) as implemented in Partek
Genomics Suite [13]. DAS was determined with one-way
ANOVA on Group (Benjamini-Hochberg false discovery rate,
FDR; p<0.05), and differential exon usage was assessed be-
tween each two groups (p<0.0005, fold change>|1.2|).
Principal components analysis (PCA) and hierarchical
clustering were performed in Partek Genomics Suite.
Ingenuity Pathway Analysis (IPA®) and DAVID identified
regulated pathways and processes as described previously [6].
Results
Subject Demographics
Subject demographics and clinical characteristics are presented
in Table 1. Only Caucasian males were studied because of the
small group sizes. Age, time since event for IS or ICH, and
vascular risk factors were not significantly different between
groups. Coverage of a wide range of post-stroke biology was
obtained by selecting patients with early (5.8 h) through late
(101.2 h) blood draw times after IS and ICH. However, the
means were similar between the stroke groups. Cardioembolic
IS post-event blood draw times were, on average, 33.7 h; large
vessel averaged 47.4 h; lacunar averaged 34.6 h; and ICH
averaged 29.4 h (Table 1).
Table 1 Subject demographics and clinical characteristics
Ischemic stroke Intracerebral hemorrhage Controls
Cardioembolic Large vessel Lacunar
Subjects (total n=20) 4 4 4 4 4
Age, years (mean±SD) 62.3±9.6 61.0±8.2 58.9±9.0 60.1±2.3 60.8±9.2
Time since event, h (mean±SD) 33.7±18.9 47.4±47.8 34.6±23.7 29.4±15.5 N/A
Hypertension 4 3 2 3 3
Diabetes 2 2 0 0 1
Hyperlipidemia 3 2 2 0 2
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RNA Sequencing Alignments
RNA sequencing alignment statistics for all samples among
the five groups are presented in Supplementary Table 1.
Cardioembolic stroke samples had on average, 1.60E+08
alignments; large vessel had 1.65E+08 alignments; lacunar
stroke had 1.64E+08 alignments; and ICH and control groups
each averaged 1.59E+08 alignments. These data show that
there is no bias in the numbers of alignments for any of the
five groups.
Distinct Alternative Splicing of Genes in Whole Blood
of Stroke Patients and Controls
A total of 412 genes displayed differential alternative splicing
(DAS) in the whole blood transcriptomes of the five groups of
Fig. 1 Principal components analysis (PCA) (Fig. 1a) and unsupervised
hierarchical clustering (Fig. 1b) of the 308 exons (292 genes) with
differential exon usage among intracerebral hemorrhage (n=4),
ischemic strokes (IS) (cardioembolic, large vessel, and lacunar) (n=12),
and control subjects (n=4). In Fig. 1a, the expression of the 308 exons is
compressed on to three axes in the PCA plot. The three principal
components on the PCA plot account for 64.1 % of the variance. In
Fig. 1b, exon expression is shown on the X-axis and subjects are shown
on the Y-axis. Each row on the Y-axis represents a single individual, with
five individuals per group. The dendrograms were removed from this
figure. Red indicates increased expression. Green indicates decreased
expression
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patients with ischemic stroke (cardioembolic, large vessel, and
lacunar), intracerebral hemorrhage (ICH) and controls (FDR
p<0.05; Supplementary Table 2, raw reads; Supplementary
Table 3, ANOVA results). These 412 genes are those predicted
using the E/M algorithm [13] as implemented in Partek, to
have DAS for IS (cardioembolic, large vessel, lacunar) versus
ICH versus controls. The E/M algorithm probabilistically as-
signs reads to known isoforms/exons of a gene [13]. Partek
then uses a log-likelihood ratio test to identify genes with
DAS across samples [13, 14]. The 412 significant genes
displaying DAS across IS, ICH, and controls are involved in
cellular immunity, cytokine signaling, and cell death and sur-
vival pathways (Supplementary Table 4).
Pathways highly over-represented with differentially alter-
native spliced genes between the five groups included CD28
signaling in T helper cells, CDC42 signaling, Nur77 signaling
in T lymphocytes, fMLP signaling in neutrophils, and inter-
feron signaling (Supplementary Table 4). Molecular and cel-
lular functions most highly associated with the differentially
alternatively spliced genes were cell death and survival of
immune cells, cell-cell signaling, activation and recruitment
of leukocytes, antigen-presenting cells, activation of T lym-
phocytes, adhesion of vascular endothelial cells, and immune
response of neutrophils (Supplementary Table 5).
Specific Exon-Usage Profiles for ICH and Different
Ischemic Stroke Etiologies
A total of 308 exons from 292 genes were differentially
expressed for the three causes of IS (cardioembolic, large ves-
sel, lacunar), ICH, and controls (p<0.0005, fold change >|1.2|;
Supplementary Table 6, raw reads; Supplementary Table 7,
ANOVA results). These exons separated the five groups, in-
cluding the three causes of IS (cardioembolic, large vessel,
lacunar), ICH, and controls on principal components analysis
(PCA) plots (Fig. 1a) and using unsupervised hierarchical
clustering (Fig. 1b). Given that the E/M algorithm uses counts
of the numbers of reads on each exon [13, 14], the differential
expression of exons across the five groups represents differ-
ential exon usage across the five groups. These results are
relevant to DAS because DAS results from differential exon
usage.
Biological functions and networks represented by genes
with differentially expressed exons in each group (Fig. 1b)
are summarized in Supplementary Table 8. Cardioembolic
stroke genes with differential exon usage were involved in
ion binding/transport and cellular assembly/organization.
Large-vessel stroke genes were associated with cell death,
transcription, and chromatin remodeling. Lacunar stroke
genes were associated with cellular compromise, cell cycle,
cell death and survival. ICH genes were involved with protein
transport and localization (Supplementary Table 8).
Discussion
Although differential alternative splicing (DAS) is implicated
in many human diseases, this is the first study to show that
DAS differs between intracerebral hemorrhage (ICH), ische-
mic stroke, and control subjects. In addition, it is the first study
to show that DAS differs between different etiologies of is-
chemic stroke including cardioembolic, large vessel, and la-
cunar causes. Identification of DAS in RNA from whole
blood for specific stroke etiologies and ICH suggests the im-
mune response varies for each condition. This will be impor-
tant for understanding the pathogenesis of each condition and
will be important for developing biomarkers to differentiate
ischemic stroke from ICH and for developing biomarkers to
differentiate the different causes of ischemic stroke.
This study identified several pathways, molecular func-
tions, and genes previously reported in human ischemic stroke
using 3′-biased microarrays [6, 15]. These included actin cy-
toskeleton signaling, CCR5 signaling in macrophages, NF-κB
activation, α-adrenergic signaling, cellular growth and prolif-
eration, cell death and survival, cell morphology, hematopoi-
esis, hematological system development, and inflammatory
response [4, 5, 16, 17]. Moreover, a number of the pathways
implicated in different etiologies of ischemic stroke in our
previous microarray studies were confirmed in these RNA-
seq studies [4, 5, 16, 17].
This study is the first to describe genes with DAS and
pathways unique for ICH. Among the genes that differentiated
ICH from IS were INPP5D (inositol polyphosphate-5-phos-
phatase) and ITA4 (integrin alpha 4). The INPP5D enzyme
regulates myeloid cell proliferation and programming, and its
expression correlates with hemorrhagic transformation of is-
chemic stroke [18]. ITA4 is involved in leukocyte recruitment
after intracerebral hemorrhage [19], and leukocytes are inti-
mately associated with ICH. For example, leukocytes are in-
volved in clotting and interact with injured vessels and brain
following ICH [15].
Other genes with DAS associated with ICH in this study
included NAV1 (neuron navigator 1), PDGFC (platelet de-
rived growth factor C), and CCM2 (cerebral cavernous mal-
formation 2) which participate in vascular endothelial growth
factor (VEGF) signaling, which predisposes the brain to hem-
orrhage because of new vessel formation [20]. Of interest,
mutations of CCM2 cause cerebral cavernous malformations
which can lead to intracerebral hemorrhage [21]. Other genes
with DAS associated with ICH included EXOSC1 (exosome
component 1) and EXOSC9 (exosome component 9) which
code for core components of the exosome complex [22].
Although exosomes have been implicated in neuroinflamma-
tion, neurodegeneration, and cancer, they have not previously
been associated with ICH [23, 24]. Lastly, another gene with
DAS associated with ICH included DGCR8 (DiGeorge syn-
drome critical region 8, a microprocessor complex subunit)
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which is involved in the biogenesis of microRNAs [25],
which could suggest that miRNAs are involved with differen-
tial alternative splicing following ICH.
Study Limitations
Sample sizes in this pilot study were small. Thus, we cannot rule
out splicing changes due to vascular risk factors. However, hier-
archical clustering of the differentially expressed exons demon-
strates separation on diagnosis and not on vascular risk factors
(Supplementary Figure 2). Validation of these findings in a sep-
arate cohort is needed to confirm the present results. These results
are important because they provide evidence for differential al-
ternative splicing in the pathophysiology of the immune response
to ischemic stroke and intracerebral hemorrhage and also might
provide novel biomarkers for ICH and different causes of IS.
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